Core Insights - Adaptive Biotechnologies Corporation's clonoSEQ test is gaining recognition as a standard-of-care tool for personalizing patient care and accelerating drug development, with a record-setting presence at the upcoming ASH meeting [1][2] - The inclusion of clonoSEQ in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology (ASH) highlights its integral role in modern lymphoid cancer care [1][2] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [6] - The company aims to develop immune-driven clinical products tailored to individual patients, leveraging its proprietary immune medicine platform [6][8] Product Details - clonoSEQ is the first and only FDA-cleared in vitro diagnostic test for detecting and tracking minimal residual disease (MRD) in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, among others [3][4] - The test can identify and quantify DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, which aids in assessing and monitoring MRD with precision [4] Clinical Impact - The abstracts featuring clonoSEQ data cover various blood cancers, underscoring its position as the most widely used and validated next-generation sequencing-based MRD test in lymphoid malignancies [7] - More than 17 presentations will demonstrate how clonoSEQ MRD assessment informs treatment decisions in real-world clinical practice across multiple cancer types [7]

Core Points - GXO Logistics, Inc. has completed its first European bond offering, issuing €500 million in senior unsecured notes with a 3.750% annual interest rate, maturing on November 24, 2030 [1][2] - The bond offering is seen as a significant milestone for GXO as an investment-grade issuer, reflecting strong investor confidence in the company's business model [2] - Proceeds from the bond will be used to refinance upcoming maturities, thereby strengthening the company's balance sheet and positioning it for long-term growth [2] Company Overview - GXO Logistics, Inc. is the world's largest pure-play contract logistics provider, focusing on the growth of e-commerce, automation, and outsourcing [3] - The company employs over 150,000 team members across more than 1,000 facilities, totaling over 200 million square feet [3] - GXO serves leading blue-chip companies, providing advanced supply chain and e-commerce solutions [3]

Core Insights - Biogen Inc. and Dayra Therapeutics have announced a research collaboration focused on developing oral macrocyclic peptides for immunological conditions, aiming to disrupt traditional antibody-based treatments [1][2][8] - The collaboration is expected to enhance Biogen's immunology portfolio by incorporating a new class of therapeutics that can be administered orally while maintaining biologic-like efficacy and safety [2][8] Company Overview - Biogen, founded in 1978, is a leading biotechnology company dedicated to innovative science and the development of new medicines to improve patient lives and create shareholder value [4] - Dayra Therapeutics, established in 2024, specializes in oral macrocyclic peptide therapeutics, utilizing a discovery platform that combines computational design and modeling to target disease-relevant proteins [6] Financial Terms - Under the collaboration agreement, Dayra Therapeutics will receive a $50 million upfront payment from Biogen, which will be recorded as an Acquired In-Process Research and Development expense in Q4 2025 [3] - Biogen has the option to acquire development candidates from Dayra for additional payments per program, along with potential preclinical and clinical milestone payments [3]

Core Insights - The CREST-2 study demonstrated that carotid artery stenting combined with intensive medical therapy significantly reduces the risk of stroke compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis [1][2][4] - The study results were presented at major medical conferences and published in the New England Journal of Medicine, marking a pivotal moment for the treatment of carotid disease [1][4] Study Details - CREST-2 was a NIH-sponsored clinical trial involving 155 centers globally, comparing outcomes of carotid artery stenting plus intensive medical management against intensive medical management alone [4] - The primary outcome measured was a composite of any stroke or death, assessed from randomization to 44 days, or ipsilateral ischemic stroke during the follow-up period of up to 4 years [4] - A total of 1245 patients were randomized in the stenting trial, while 1240 patients were randomized in the endarterectomy trial [4] Company Positioning - InspireMD's CGuard Prime carotid stent system is positioned as a leading option for carotid stenting, supported by the positive CREST-2 results and over 65,000 global implants [3][5] - The company emphasizes the effectiveness of its MicroNet™ mesh technology in achieving low adverse event rates, with a reported 1.93% major adverse event rate through 12 months in high surgical risk patients [3]

MONTREAL, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") is pleased to announce that it has entered into a securities purchase agreement dated November 21, 2025 (the "Purchase Agreement") with Axo Copper Corp. (TSXV:AXO) ("Axo") to sell its 100% interest in the San Antonio Gold Project ("San Antonio" or the "Project") located in the Sonora State, Mexico. Pursuant to the Purchase Agreement, Axo will acquire Sapuchi Minera S.A. de R.L. ...

Core Viewpoint - Chijet Motor Company has signed a definitive agreement to acquire up to $1 billion in EdgeAI tokens at a 20% discount, enhancing its position in the digital asset space and providing immediate economic benefits [1][5]. Group 1: Agreement Details - The agreement is expected to generate approximately $200 million in upfront value for Chijet compared to current market rates [2]. - Chijet will act as a validator node on the EdgeAI blockchain network, allowing the company to earn staking rewards and generate recurring revenue [3]. - The partnership has an initial term of five years, with all activities conducted in compliance with internal governance policies and regulatory requirements [4]. Group 2: Strategic Implications - The acquisition of digital assets is seen as a way to diversify Chijet's portfolio and bridge traditional manufacturing with the digital economy [5]. - EdgeAI will serve as the primary advisor on digital assets, providing expertise in token acquisition strategies and treasury management [2]. Group 3: Company Background - Chijet specializes in the development, manufacture, sales, and service of traditional fuel vehicles and new energy vehicles, with a focus on high performance and reasonable pricing [7]. - The company has a modern vehicle production base in Jilin, China, and is constructing a factory in Yantai dedicated to new energy vehicle production [7].

Core Insights - Green Rain Energy Holdings Inc. has initiated Regulation Crowdfunding (Reg CF) through its subsidiary, Green Rain Development, to raise capital by offering fractional ownership to a diverse range of investors [1][9] - The company aims to accelerate the development of electric vehicle (EV) charging stations, solar farms, and battery component projects across North America, aligning with its mission to transform urban environments into sustainable energy hubs [2] - The announcement coincides with the distribution of a special share dividend, reinforcing the company's commitment to shareholder value and indicating that Reg CF is a pivotal tool for engaging qualified investors in the renewable energy sector [4] Company Strategy - Through Green Rain Development, the company plans to integrate innovative EV infrastructure and establish local partnerships to expedite renewable energy projects, supporting both environmental responsibility and long-term value creation for investors and communities [3] - The company is dedicated to developing sustainable power solutions across North America, building a robust clean energy infrastructure that includes solar generation and EV charging networks [5]

How Mine Expansion to 55,000 Tonnes Per Month Targeting H2 2026 Operational DateEnabling Works Commenced at Redwing; 8-Month Dewatering Program to BeginCompany Outlines $300-400 Million Capital Plan with Non-Dilutive Funding StrategyManagement to Host Business Update Conference Call at 8:00 a.m. Eastern Time NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Namib Minerals (“Namib Minerals” or “the Company”), (Nasdaq: NAMM), an established African gold producer with a portfolio of mining and exploration assets in ...

Core Insights - Clearside Biomedical, Inc. has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware, aiming to maximize stakeholder value through a structured auction and sale process [1][3][2] Company Overview - Clearside is a biopharmaceutical company focused on revolutionizing therapy delivery to the back of the eye via the suprachoroidal space (SCS) [17] - The company has developed the SCS Microinjector, which allows for targeted, non-surgical delivery of therapies to treat various sight-threatening eye diseases [17][11] Financial and Operational Strategy - The company intends to continue normal operations during the bankruptcy process and has filed motions to facilitate this [2] - Clearside's assets include a clinically validated SCS Microinjector platform, multiple licensing agreements, and a pipeline of product candidates, including the CLS-AX program for wet AMD and diabetic retinopathy [2][12] Product Pipeline - The SCS Microinjector has received FDA approval for its first product, XIPERE, which is used for treating uveitic macular edema [7][14] - The CLS-AX program is in advanced clinical stages, with positive results from Phase 1/2a and Phase 2b trials for wet AMD, and plans for a Phase 3 trial are underway [12][16] Licensing and Partnerships - Clearside has established multiple licensing agreements for its SCS Microinjector technology, partnering with companies like Bausch + Lomb and AbbVie [11][12] - The company has also engaged in a Purchase and Sale Agreement to manage royalty rights related to its products, enhancing its financial position [12]

Core Viewpoint - Invivyd, Inc. has identified a potentially best-in-class monoclonal antibody candidate, VBY329, for the prevention of Respiratory Syncytial Virus (RSV) in neonates, infants, and children, leveraging its proprietary antibody discovery technology [1][5][6] Group 1: Product Development - VBY329 demonstrates in vitro properties that indicate higher potency and improved resistance compared to existing treatments like nirsevimab and clesrovimab, with an antiviral potency 1.5-fold greater than nirsevimab and 1.2-fold greater than clesrovimab [2][6] - The antibody candidate shows up to approximately 500-fold enhanced neutralization activity against RSV F protein variants resistant to nirsevimab, indicating a strong resistance profile [6] - Invivyd aims to achieve IND readiness for VBY329 in the second half of 2026, with plans to present in vitro data at a future medical congress [3][6] Group 2: Market Potential - The market for RSV prophylaxis among children under 24 months is projected to grow significantly, with expectations of reaching $3-$4 billion in annual revenues globally by 2030 [3][6] - Monoclonal antibodies have been a critical treatment option for vulnerable populations for nearly 30 years, suggesting a robust market opportunity for VBY329 [3] Group 3: Company Overview - Invivyd, Inc. is focused on developing innovative monoclonal antibodies for serious viral infectious diseases, with a unique integrated technology platform for antibody assessment and development [7] - The company has previously received emergency use authorization from the U.S. FDA for another monoclonal antibody, highlighting its capability in the biopharmaceutical sector [7]